Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
OncoSil Medical Ltd ( (AU:OSL) ) has provided an announcement.
OncoSil Medical Limited has announced a change in its registered office address to Level 5, 7 Eden Park Drive, Macquarie Park, NSW 2113, Australia. This change is part of the company’s compliance with ASX Listing Rule 3.14. The move is a procedural update and does not indicate any strategic shift or operational impact on the company’s focus or market positioning.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a global medical device company specializing in Interventional Oncology. The company focuses on improving cancer treatment outcomes through the intratumoural placement of Phosphorous-32 (32P) Microparticles, particularly for unresectable locally advanced pancreatic cancer. Their OncoSil™ device offers a targeted approach to deliver higher radiation doses directly to tumors while minimizing damage to surrounding organs. The device has received CE Marking approval and is recognized as a breakthrough device in both Europe and the United States, with approval for sale in over 30 countries.
Average Trading Volume: 40,709
Technical Sentiment Signal: Sell
Current Market Cap: A$21.08M
For a thorough assessment of OSL stock, go to TipRanks’ Stock Analysis page.